List of Excipients in Branded Drug ANTARA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lupin Pharmaceuticals Inc	ANTARA	fenofibrate	27437-107	D&C YELLOW NO. 10
Lupin Pharmaceuticals Inc	ANTARA	fenofibrate	27437-107	DIMETHICONE
Lupin Pharmaceuticals Inc	ANTARA	fenofibrate	27437-107	FD&C BLUE NO. 2
Lupin Pharmaceuticals Inc	ANTARA	fenofibrate	27437-107	FERRIC OXIDE YELLOW
Lupin Pharmaceuticals Inc	ANTARA	fenofibrate	27437-107	FERROSOFERRIC OXIDE
Lupin Pharmaceuticals Inc	ANTARA	fenofibrate	27437-107	GELATIN
Lupin Pharmaceuticals Inc	ANTARA	fenofibrate	27437-107	HYPROMELLOSES

Antara Excipient Strategy and Commercial Opportunities for Fenofibrate Capsules

Last updated: August 31, 2026

Antara is a historical U.S. brand of micronized fenofibrate, marketed in 43 mg and 87 mg capsules for hypercholesterolemia and hypertriglyceridemia. Its commercial value is no longer driven by brand exclusivity. The opportunity is in generic or authorized-generic development, differentiated fenofibrate delivery, excipient substitution, supply-chain resilience, and lifecycle products that improve food-effect performance or patient tolerability.

The core formulation challenge is fenofibrate’s very low aqueous solubility. Micronization and wetting support are central to product performance. Excipient changes that alter particle dispersion, wetting, capsule disintegration, or dissolution can affect bioequivalence and may require comparative dissolution, pharmacokinetic, and regulatory work.

What drug is Antara and which excipients define its formulation?

Antara contains micronized fenofibrate, a fibric-acid derivative that lowers triglycerides and low-density lipoprotein cholesterol while increasing high-density lipoprotein cholesterol. The product was supplied as oral capsules in 43 mg and 87 mg strengths. Historical U.S. labeling identifies conventional solid-dosage excipients used to support powder flow, capsule filling, wetting, disintegration, and release [1].

Antara formulation profile

Attribute	Antara profile
Active ingredient	Fenofibrate
Dosage form	Hard gelatin capsule
Historical strengths	43 mg and 87 mg
API form	Micronized fenofibrate
Primary formulation problem	Poor aqueous solubility
Key performance variables	Particle-size distribution, wetting, dispersion, dissolution
Main regulatory route for competition	Abbreviated New Drug Application, or ANDA
Therapeutic category	Lipid-modifying agent
Primary commercial competitors	Generic fenofibrate capsules and tablets, Tricor, Triglide, Lipofen, Fenoglide

The excipient system should be analyzed by function rather than by ingredient count:

1. A wetting or surfactant component improves contact between fenofibrate particles and gastrointestinal fluid.
2. A disintegrant promotes rapid breakup of the capsule fill.
3. A glidant and lubricant control powder flow and capsule-filling performance.
4. A diluent adjusts bulk density and dose uniformity.
5. The gelatin shell determines moisture exposure, mechanical integrity, color, and patient acceptability.

Historical Antara labeling included conventional excipient classes such as lactose or other fillers, disintegrant materials, surfactant support, silicon dioxide or equivalent glidant, and magnesium stearate or another lubricant. Exact inactive-ingredient composition should be taken from the applicable approved label and product-specific regulatory record because manufacturing sites and capsule-shell specifications can change over time [1].

How does fenofibrate solubility affect the excipient strategy?

Fenofibrate is a poorly water-soluble compound. For this type of API, formulation performance depends less on simple capsule disintegration than on the rate and extent of drug wetting, deagglomeration, and dissolution.

Critical quality attributes

A commercial Antara-equivalent product should control:

• API particle-size distribution and micronization energy.
• Agglomeration during blending and storage.
• Blend uniformity at the 43 mg and 87 mg dose levels.
• Powder flow into the capsule body.
• Surfactant distribution across the blend.
• Disintegration time.
• Dissolution under relevant pH and surfactant conditions.
• Moisture uptake by the powder and capsule shell.
• Stability of the fill-shell interaction.

The most important excipient risks are over-lubrication, insufficient wetting, and segregation. Excess magnesium stearate can create hydrophobic powder surfaces and slow dissolution. Excessive surfactant can complicate taste, gastrointestinal tolerability, powder handling, and capsule-shell compatibility. A coarse or poorly distributed disintegrant can produce acceptable disintegration results while still generating inadequate dissolution.

Excipient screening priorities

A development program should compare:

Formulation variable	Commercial purpose	Main risk
Surfactant level	Improve wetting and dissolution	Tolerability, foaming, blend uniformity
Crospovidone or equivalent disintegrant	Accelerate capsule-fill breakup	Variable swelling and dissolution
Lactose, MCC, starch, or alternative filler	Adjust bulk density and fill weight	Segregation, moisture sensitivity
Colloidal silicon dioxide	Improve flow	Dusting and over-drying
Magnesium stearate	Improve manufacturing performance	Dissolution retardation if overused
HPMC capsule shell	Vegetarian positioning and moisture control	Different shell performance and cost
Gelatin capsule shell	Conventional performance and lower switching risk	Animal-origin restrictions

What excipient changes are most commercially attractive?

The strongest near-term opportunities are low-risk substitutions that preserve the historical release profile while addressing procurement, regulatory, or patient-use concerns.

Lactose-free fenofibrate capsules

A lactose-free product can target patients with lactose intolerance, excipient avoidance preferences, and institutional formularies that favor simplified inactive-ingredient profiles. Microcrystalline cellulose, mannitol, anhydrous dibasic calcium phosphate, or starch-based fillers can replace lactose, but each changes density, flow, moisture behavior, and capsule-fill volume.

Mannitol may improve mouthfeel and provide a differentiated inactive-ingredient profile, but its hygroscopicity and density must be managed. Microcrystalline cellulose is widely available and usually offers robust compaction and flow support, although excessive use can slow wetting in hydrophobic systems.

Low-surfactant or surfactant-free systems

A lower-surfactant formulation may appeal to patients and buyers seeking fewer excipients. It carries the highest technical risk because fenofibrate dissolution can deteriorate when wetting support is reduced. A surfactant-free product would likely require stronger particle engineering, a solid-dispersion approach, or a different delivery platform.

The commercial case is strongest where the product can demonstrate equivalent exposure with a cleaner excipient profile. The development burden is higher than for a conventional generic because formulation changes may affect both in vitro dissolution and in vivo food-effect behavior.

HPMC capsules

Hydroxypropyl methylcellulose capsules offer an animal-origin-free alternative to gelatin. They can support vegetarian, halal, kosher, and institutional procurement strategies. The shell can differ from gelatin in moisture content, brittleness, dissolution, and interaction with hygroscopic fills. A shell change should be evaluated as a product-performance change, not a cosmetic substitution.

Moisture-controlled formulations

Fenofibrate capsules may benefit from improved moisture-barrier packaging, desiccant systems, or shell selection. These changes can reduce clumping, preserve powder flow, and improve shelf-life robustness. Packaging is often a lower-risk commercial lever than changing the core excipient system.

What formulations are protected by Antara-related intellectual property?

Antara’s original commercial differentiation was based on micronized fenofibrate in a capsule dosage form. The broader fenofibrate market includes patents and regulatory exclusivities associated with specific formulations, particle engineering, tablets, capsules, and absorption-enhancing systems.

The basic active ingredient is old, and conventional micronized fenofibrate is exposed to generic competition. The remaining intellectual-property value generally sits in:

• Specific particle-size distributions.
• Solid dispersions or carrier systems.
• Nanoparticle or enhanced-dissolution formulations.
• Modified-release systems.
• Combination products.
• Manufacturing processes that produce a defined dissolution profile.
• Method-of-use claims, where still enforceable.
• Device or packaging claims for specialized delivery systems.

A developer should not assume that a formulation patent blocks all fenofibrate products. Freedom to operate must be assessed claim by claim, including prosecution history, terminal disclaimers, continuity applications, patent-term adjustments, and Orange Book listing status.

When did Antara lose exclusivity and what is the generic entry risk?

Antara is a mature product. Its principal commercial protection was not expected to remain a meaningful barrier once conventional fenofibrate products gained approval. The practical generic risk is high for a conventional capsule that matches the reference product’s strength, dosage form, composition strategy, and performance profile.

Exclusivity and patent considerations

Issue	Antara assessment
New chemical entity exclusivity	Expired or no longer commercially relevant
Conventional active-ingredient protection	Expired or commercially weak
Formulation patent risk	Depends on the specific reference product and claim set
Orange Book relevance	Must be verified against the current FDA listing
Paragraph IV exposure	Possible for any unexpired listed patent
Generic pathway	Primarily 505(j), subject to product-specific requirements
Biosimilar risk	None; fenofibrate is a small molecule
Substitution risk	Depends on FDA therapeutic-equivalence rating and dosage form

Fenofibrate products cannot be evaluated as a single interchangeable category. Tablets, capsules, micronized products, and enhanced-bioavailability products may have different reference products and different bioequivalence requirements. The FDA Orange Book should be used to confirm current patents, exclusivity, and therapeutic-equivalence codes for the specific reference listed drug [2].

What FDA regulatory issues affect an Antara-equivalent product?

The central FDA issue is bioequivalence for a poorly soluble, food-sensitive drug. A generic applicant must show that the proposed product performs comparably to the reference product under the applicable study conditions.

Key regulatory workstreams

A conventional ANDA program should address:

1. Pharmaceutical equivalence in strength, dosage form, route, and active ingredient.
2. Comparative dissolution using discriminatory methods.
3. Fed and fasted pharmacokinetic studies where required.
4. Particle-size and micronization controls.
5. Stability under long-term and accelerated conditions.
6. Capsule-shell equivalence or justification for an alternative shell.
7. Inactive-ingredient qualification.
8. Impurity and residual-solvent control.
9. Manufacturing validation for low-dose blend uniformity.

Food effect is a significant commercial and regulatory issue. Fenofibrate products historically have differed in how much they depend on food for absorption. A formulation that reduces food dependence could support premium positioning, but it may no longer qualify as a simple formulation copy if the reference product’s performance characteristics differ materially.

Which companies are challenging Antara and what is the competitive landscape?

Competition comes from generic fenofibrate manufacturers and from branded or authorized-generic products associated with other fenofibrate formulations. Relevant market participants have included manufacturers of generic fenofibrate capsules and tablets, as well as holders of brands such as Tricor, Triglide, Lipofen, and Fenoglide.

The competitive landscape is segmented:

Segment	Competitive basis	Margin outlook
Standard generic capsule	Lowest cost and broad distribution	Low
Lactose-free capsule	Patient and institutional differentiation	Low to moderate
HPMC capsule	Animal-origin-free positioning	Moderate
Enhanced-dissolution product	Performance and potential food-effect benefit	Moderate to high
Specialty formulation	IP, clinical differentiation, or adherence benefit	Highest but highest risk
Contract-manufactured private label	Supply reliability and price	Low

A new entrant competing only on price faces limited differentiation. The more attractive strategy is a reliable, easily substituted product with a documented supply advantage, or a differentiated formulation supported by a clear regulatory and reimbursement rationale.

What commercial opportunities exist for excipient suppliers and CDMOs?

Excipient suppliers can create value through co-development rather than commodity supply. The most attractive opportunities include:

• Direct-compression and capsule-fill systems for low-dose fenofibrate.
• Low-moisture fillers and flow aids.
• Higher-performance wetting agents.
• Co-processed excipients that reduce segregation.
• Animal-origin-free capsule shells.
• Packaging systems that reduce humidity exposure.
• Ready-to-use premixes with validated dissolution performance.

CDMOs can offer a stronger proposition by combining micronization, formulation screening, capsule filling, analytical dissolution, and ANDA-supporting stability work. A supplier that controls both particle engineering and excipient distribution can reduce the risk that changes in one process undermine the other.

How strong is the patent estate for Antara compared with newer fenofibrate products?

Antara’s conventional capsule concept has a weaker long-term exclusivity profile than newer delivery platforms. Its defensibility depends primarily on manufacturing know-how, reference-product similarity, supply reliability, and regulatory execution rather than on broad composition-of-matter rights.

A newer fenofibrate product may have stronger protection if it claims a defined solid dispersion, nanoparticle architecture, absorption-enhancing carrier, or clinically demonstrated reduction in food dependence. That protection can support higher pricing, but it also increases development cost and patent litigation exposure.

For a generic entrant, the preferred path is usually to avoid unnecessary infringement risk by reproducing the reference product’s functional performance with a non-infringing excipient composition. For an innovator, the preferred path is to claim measurable performance attributes that are difficult to design around, such as dissolution behavior linked to a defined particle-carrier structure.

What litigation and settlement issues affect Antara?

Antara-related litigation risk is generally lower than for high-revenue protected medicines because fenofibrate is a mature small-molecule market. The principal legal risks arise when a formulation patent remains listed or when a new product relies on a formulation with active patent claims.

A Paragraph IV notice can create litigation under the Hatch-Waxman framework, potentially triggering a 30-month stay of approval for an ANDA under qualifying conditions [3]. Settlement agreements should be reviewed for:

• First-filer status.
• Authorized-generic provisions.
• Launch-date restrictions.
• Supply or licensing commitments.
• Acceleration clauses.
• Restrictions on formulation or strength.
• Antitrust exposure from delayed-entry terms.

There is no biosimilar pathway for Antara because fenofibrate is a chemically synthesized small molecule, not a biologic.

How should an Antara excipient strategy be prioritized?

The best commercial sequence is:

1. Develop a conventional, bioequivalent capsule with robust micronization and dissolution controls.
2. Evaluate lactose-free and HPMC-shell variants as low-to-moderate-risk line extensions.
3. Add moisture-barrier packaging and multi-site excipient sourcing.
4. Screen low-surfactant systems only after establishing a reliable reference-like baseline.
5. Pursue enhanced-dissolution or reduced-food-effect products only with a credible patent and clinical differentiation strategy.

The first product should prioritize approval probability and manufacturing reliability. Differentiated excipients should be introduced where they solve a defined market problem, not merely to increase the inactive-ingredient count.

Key Takeaways

• Antara is a historical micronized fenofibrate capsule product in 43 mg and 87 mg strengths.
• Fenofibrate’s low solubility makes wetting, particle size, blend uniformity, and dissolution the key formulation controls.
• Conventional generic competition faces high entry risk but low patent-based barriers.
• Lactose-free fillers, HPMC capsules, moisture-control systems, and improved flow aids are the most practical excipient opportunities.
• Surfactant reduction or elimination is commercially attractive but technically higher risk.
• A new formulation with reduced food dependence or enhanced dissolution may support stronger differentiation and patent protection.
• FDA approval strategy should focus on product-specific bioequivalence, food-effect performance, dissolution, and Orange Book review.
• The strongest commercial position combines reference-like performance with supply-chain resilience and a targeted inactive-ingredient advantage.

FAQs

Can Antara be reformulated as a tablet?

Yes. Fenofibrate is marketed in multiple dosage forms, including tablets and capsules. A tablet conversion would require a product-specific bioequivalence strategy and may not be substitutable with an Antara-equivalent capsule without the appropriate FDA therapeutic-equivalence determination.

Is a lactose-free Antara generic commercially viable?

Yes. A lactose-free product can differentiate in institutional purchasing and patient-excipient preference segments. The formulation must preserve powder flow, capsule-fill uniformity, dissolution, and bioequivalence.

Can HPMC capsules improve the commercial positioning of fenofibrate?

Yes. HPMC capsules can support vegetarian and animal-origin-free positioning. The shell change requires evaluation of moisture, mechanical strength, disintegration, dissolution, and stability.

Does fenofibrate require a Paragraph IV strategy?

Only if the proposed ANDA relies on a certification against an unexpired Orange Book-listed patent. For a mature conventional fenofibrate product, applicants must confirm the current FDA-listed patents and exclusivity before selecting Paragraph I, II, III, or IV certifications.

Are excipient patents important for fenofibrate products?

They can be. Protection may attach to a specific carrier, solid dispersion, particle-engineering process, dissolution profile, or manufacturing method. Commodity excipients alone usually provide limited exclusivity unless used within a claimed formulation architecture.

References

1. U.S. Food and Drug Administration. (n.d.). Antara (fenofibrate) capsules prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman letters and abbreviated new drug application patent certifications. FDA.
4. U.S. Food and Drug Administration. (n.d.). Fenofibrate product-specific guidance. FDA.